Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126766
Filing Date
2024-11-14
Accepted
2024-11-14 08:30:21
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20240930.htm   iXBRL 10-Q 1435502
2 EX-31.1 ikt-ex31_1.htm EX-31.1 14028
3 EX-31.2 ikt-ex31_2.htm EX-31.2 14085
4 EX-32.1 ikt-ex32_1.htm EX-32.1 10207
5 EX-32.2 ikt-ex32_2.htm EX-32.2 10205
  Complete submission text file 0000950170-24-126766.txt   6050619

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20240930.xsd EX-101.SCH 978935
69 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20240930_htm.xml XML 867252
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 241457376
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)